Success in funding round for DestiNA Genomics

Access to quicker and more effective diagnostic tests for cancers and infectious diseases has moved a step closer after DestiNA Genomics, a University of Edinburgh spin-out company, completed a £930,000 equity investment.

The funding will provide the firm with greater capabilities to commercialise the pioneering medical tests that will ultimately benefit both patients and healthcare systems, with earlier diagnosis cutting the costs of treatment.